Comparative Efficacy and Side Effects of the Treatment of Euthyroid Goiter with Levo-Thyroxine or Triiodothyroacetic Acid

Abstract

AbstractEuthyroid goiter is usually treated with TSH-inhibitory doses of levo-T4 (l-T4). Because triiodothyroacetic acid (TRIAC) decreases TSH levels, the following study was perfomed: 36 euthyroid goitrous female patients (no cancer or chronic thyroiditis) were randomized to TRIAC (19.6 μg/kg) (n = 19) or l-T4 (1.7 μg/kg) (n = 17) treatment during 11 months. Goiter volume; lumbar and femoral bone mineral density; serum osteocalcin; deoxypyridinoline; TSH; free T4; total, high-density lipoprotein, and low-density lipoprotein cholesterol; and triglycerides were measured before and after the study period. Student’s t test and χ2 analysis were performed. TSH values (microunits per milliliter) in the TRIAC and l-T4 groups were: 1.91 ± 0.6 (basal) and 0.180 ± 0.1 (after) and 2.1 ± 2.5 (basal) and 0.180 ± 0.3 (after), respectively. Thyroid volume decreased 37.9 ± 35.4% in the TRIAC patients and 14.5 ± 39.5% in the l-T4 group (P = 0.069). Forty-two percent of the goiters with TRIAC reduced more than 50% their initial volume vs. 17.7% with l-T4 (P = 0.15). With TRIAC, patients experienced fewer side effects. No differences in the changes of bone mineral density, serum deoxypyridinoline, osteocalcin, or the lipid profile were observed between both groups. The present results show that TRIAC is more effective than l-T4 in the reduction of goiter size, with comparable effects on peripheral parameters.